How did ONCT's Q4 2023 EPS surprise investors?
4/7/2025 03:26pm
ONCT's Q4 2023 EPS fell short of investor expectations, as evidenced by an EPS surprise of -0.04. This negative surprise suggests that the company's performance in that quarter was below what investors had anticipated, potentially due to factors such as clinical trial setbacks, regulatory hurdles, or operational inefficiencies. The EPS surprise of -0.04 indicates a clear underperformance compared to the expectations of analysts, which could lead to concerns regarding the company's financial health and future prospects.
|code|Ticker|Name|Date|EPS Surprise YoY|EPS Surprise|market_code|
|---|---|---|---|---|---|---|
|ONCT|ONCT.O|Oncternal|20230331||0|186|
|ONCT|ONCT.O|Oncternal|20230630||0.01|186|
|ONCT|ONCT.O|Oncternal|20230930|-200|-0.03|186|
|ONCT|ONCT.O|Oncternal|20231231|-500|-0.04|186|